Impact of COVID-19 monoclonal antibodies on outcomes of COVID-19 infection in hematopoietic stem cell transplant and chimeric antigen receptor therapy recipients.

Elizabeth H HahnHong LiCraig S SauterSherif Beniameen Mossad

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2024)

HSCT and CAR-T recipients who received MCA following COVID-19 infection were far less likely to develop COVID-related complications than those who did not receive MCA, regardless of vaccination status. This underscores the potential benefit of developing novel MCA with efficacy against circulating COVID-19 strains.

Keyphrases

coronavirus disease
sars cov
hematopoietic stem cell
respiratory syndrome coronavirus
escherichia coli
kidney transplantation
risk factors
risk assessment
stem cells
bone marrow
adipose tissue
human health
mesenchymal stem cells
drug induced